Study design and study population
idiopathic PD
XINDI (NCT03881371) was a Phase III, double-blind, Chinese multicenter study with 305 patients treated with safinamide or placebo, as add-on to levodopa, for 16 weeks. Patients were eligible if ≥ 18 years, with idiopathic PD > 3-year duration